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TelmisartanAbstract Developed and optimized a validated isocratic reverse phase HPLC separation of Rosu-
vastatin, Telmisartan, Ezetimibe and Atorvastatin in pharmaceutical preparation using response sur-
facemethodology. The separationwas carried out by using phenomenex C18 column (15 cm · 4.6 mm
id, 5 lm particle size) and UV detection at 239 nm. The ranges of the independent variables used for
the optimization wereMeCN: 33–38%, buffer conc.: 10–20 mMand ﬂow rate: 1–2 ml/min. The inﬂu-
ence of these independent variables on the output responses: capacity factor of the ﬁrst peak (k1), res-
olutions of the 2nd and 3rd peak (Rs2,3), and capacity factor of the ﬁfth peak (k5) were evaluated.
Using this strategy, a mathematical model was deﬁned and a response surface was derived for the sep-
aration. The three responses were simultaneously optimized by using Derringer’s desirability func-
tions. Optimum conditions chosen for the assay were MeCN, MeOH, 20 mM K2HPO4 (pH
3.0 ± 0.2) solution (34.27:20:45.73 v/v/v) and ﬂow rate 2 ml/min. Total chromatographic analysis
time per sample was approximately 10 min. The optimized assay condition was validated as per the
ICH guidelines and applied for the quantitative analysis of Rosavel EZ, Avas-EZ and Lipisar 20 tab-
let. The developedmethodwas simple, accurate and precise. Hence, it can be employed for the routine
analysis in quality control laboratories.
ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
High performance liquid chromatography method develop-
ment and optimization is a well-known procedure exception-
ally for the simultaneous determination of pharmaceutical
dosage forms. Since HPLC utilizes a wide selection of several
chromatographic factors, viz., the type and composition of
the organic phase, column temperature, ﬂow rate, buffer
molarity, pH, type of the stationary phase, etc., optimization
of the experimental conditions is a complicated process. To
Chemometric technique for the optimization of chromatographic system S1379achieve this objective, any one of the chemometric methods
which includes the overlapping resolution maps (Lews et al.,
1996), factorial design (Valliappan et al., 2002) and response
surface methodology (Myers and Montgomery, 1995; Sivaku-
mar et al., 2007, 2007a,b, 2008) can be applied. In general, the
chemometrics can be used to accomplish a variety of goals in
chromatography laboratory: (i) speeding methods develop-
ment, (ii) make better use of chromatographic data and (iii) ex-
plain the chromatographic process (Matthijs et al., 2004).This
kind of knowledge provides important clues in the attainment
of optimum experimental conditions in the development of
chromatography methods (Morgan, 1991).The best experi-
mental design approach for the purpose of modeling and opti-
mization is the response surface design (Myers and
Montgomery, 1995). However, for the HPLC method intended
to be applied for the pharmaceutical or industrial environ-
ment, the analysis time is usually optimized without losing res-
olution (Deming, 1991).
When one needs to optimize more than one response at a
time the use of multicriteria decision making (MCDM), a che-
mometric technique is the best choice. The different ap-
proaches of MCDM include the path of steepest ascent,
constrained optimization procedure, Pareto-optimality, utility
function, Derringer’s desirability function. The path of steep-
est ascent can be employed only when all the response models
are linear. Constrained optimization procedure can be used
when all response models are non-linear, or when there is a
mix of linear and non-linear responses. However, this method
optimizes only one response by targeting all other responses to
appropriate constraints. When there is a mix of linear and non-
linear responses, or when all response models are linear or
non-linear, Pareto-optimality, utility function or Derringer’s
desirability function can be used. Pareto-optimality method
can basically identify the Pareto optimal region by graphical
means, but requires some additional criterion or the advice
of an expert to select one particular Pareto optimum point
(Hadjmohammadi and Safa, 2004). The Pareto-optimal meth-
od and the Derringer’s approach have their own advantages
and that the decision on which method to use depends on
the problem and the availability of chromatographic expertise.
There are many ways in which the individual desirability can
be combined. If the combined criterion is a simple arithmetic
average, it is called as utility function and if it is a geometric
mean it is referred as Derringer’s desirability function. The idea
of combining desirabilities as geometric mean was ﬁrst pre-
sented by Harrington (1965) but it was put into a more general
form by Derringer (Derringer and Suich, 1980). The advantage
of the Derringer’s desirability function is that if one of the cri-
teria has an unacceptable value, then the overall product will
also be unacceptable, while for the utility functions, this is
not the case. Further, Derringer’s method offers the user ﬂexi-
bility in the deﬁnition of desirability functions. Derringer’s
desirability function was introduced in chromatography by
Deming (1991), implementing resolution and analysis time as
objective functions to improve separation quality. Safa and
Hadjmohammadi (2005) employed Derringer’s desirability
function for the simultaneous optimization of resolution and
analysis time in micellar liquid chromatographic separation
of a group of nine phenyl thiohydantoin amino acids. Recently,
Hayashi and Matsuda (1994) proposed a chemometric tool
based on the Function of Mutual Information (FUMI) theory
to improve prediction of the uncertainty in HPLC. Kotani et al.(2003) employed FUMI theory for the prediction of
measurement R.S.D. and detection limits in HPLC-electro-
chemical detection of catechins without repetitive measurement
of chromatograms, saving considerable amounts of chemicals
and experimental time. Among the various above options, the
Derringer’s desirability functions were successfully employed.
We have recently employed the same MCDM approach
(Derringer’s desirability function) for the development and opti-
mization of a HPLCmethod for the simultaneous estimation of
pantoprazole and domperidone (Sivakumar et al., 2007b),
amlodipine and atorvastatin (Sivakumar et al., 2007) in quality
control and plasma samples.
Atorvastatin (AT) (Fig. 1), (3R,5R)-7-[2-(4-ﬂuorophenyl)-3-
phenyl-4-(phenylcarbamoyl)-5-(propan-2-yl)-1H-pyrrol-1-yl]-3,
5-dihydroxyheptanoic acid and rosuvastatin (RS) (Fig. 1),
(3R,5R,6E)-7-[4-(4-ﬂuorophenyl)-2-(N-methylmethanesulfonam-
ido)-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic
acid belong to the statin class of drugs used to treat hypercholes-
terolemia both in patients with established cardiovascular
disease as well as those who are at a high risk of developing
atherosclerosis. These drugs inhibit the rate limiting key
enzyme known as 3-hydroxy-3-methylglutarylcoenzyme A
(HMG-CoA) reductase involved in cholesterol biosynthesis.
Until the approval of rosuvastatin in 2003, atorvastatin was
the most efﬁcacious drug in the statins class (Jones et al.,
1998) but recent studies reported rosuvastatin as a potent
inhibitor of HMG-CoA reductase having a higher LDL-
lowering effect as compared with other statins (Jones et al.,
2003; McTaggart, 2003), which demonstrates that both
rosuvastatin and atorvastatin are the leading drugs in the
statins class.
Ezetimibe (EZ) (Fig. 1), (3R,4S)-1-(4-ﬂuorophenyl)-3-[(3S)-
3-(4-ﬂuorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azeti-
dine-2-one is a selective cholesterol absorbtion inhibitor, which
potently inhibits the absorption of biliary and dietary choles-
terol (Van Heek et al., 1997) from the small intestine without
affecting the absorption of fat-soluble vitamins, triglyceride
or bile acids. Clinical studies have shown that co-administra-
tion of ezetimibe with statins could provide signiﬁcant reduc-
tions in both the low-density lipoproteins (LDL) and the
total cholesterol with slight increase in the high-density lipo-
proteins (HDL) (Ballantyne et al., 2003; Davidson et al.,
2002; Kerzner et al., 2003; Melani et al., 2003). Also co-admin-
istration of ezetimibe with statins could signiﬁcantly reduce the
risk of coronary heart disease (CHD) events in patients with
hypercholesterolemia.
Telmisartan (TL) (Fig. 1), 2-(4-{[4-methyl-6-(1-methyl-1H-
1,3-benzodiazol-2-yl)-2-propyl-1H-1,3-benzodiazol-1-yl]methyl}
phenyl)benzoic acid is a new highly selective, non-peptide
angiotensin II type 1 (AT1)-receptor antagonist angiotensin
that lowers blood pressure through blockade of the renin–
angiotensin–aldosterone system (RAAS) (Neutel and
Smith,1998) and widely used in treatment of hypertension. It
can selectively block the angiotensin type I (AT1) receptor,
which is responsible for vasoconstriction and for salt and water
retention. The therapywith this drug offers a good quality of life
for hypertensive patients due to the absence of side effects and its
once daily administration. Telmisartan has become one of the
most important advances in the treatment of hypertension.
Cardiovascular therapy usually involves different combina-
tion of antihypertensive and lipid lowering drugs. Therefore
the simultaneous determination of these analytes becomes
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Figure 1 The chemical structures of analytes and internal standard (IS).
S1380 V. Sree Janardhanan et al.motivating and signiﬁcant. In the present work, a HPLC
method was developed, optimized and validated for the rou-
tine quality control analysis of RS, TL, EZ and AT from com-
mercial preparations.
The present manuscript describes (i) the development, opti-
mization and validation of an isocratic reversed-phase HPLC
method for the routine quality control analysis of RS, TL,
EZ and AT in a pharmaceutical laboratory and (ii) provide
information on sensitivity of the chromatographic factors
and their interaction effect on the separation characteristics.
In the ﬁrst step, the factorial design was employed to identify
the signiﬁcance of the curvature term for all the (k1, Rs2,3 and
k5) chromatographic responses. Subsequently, the chromato-
graphic factors that had the signiﬁcant effect were optimized
using a central composite design and response surface analysis.
Derringer’s desirability function was successfully employed to
explore the user ﬂexibility of this technique in selecting opti-
mum chromatographic conditions for the determination of
drugs in a variety of sample matrices.
2. Material and methods
2.1. Apparatus
Chromatographic measurements were made on a Shimadzu
(Tokyo, Japan) model which consisted of a LC10AD and
LC10 ADvp solvent delivery module, SPD 10A UV–Visible
detector, a Rheodyne injector (model 7125, USA) valve ﬁtted
with a 20 ll loop, and UV detector (SPD-10A). The systemwas controlled through a system controller (SCL-10A) and a
personal computer using a Shimadzu chromatographic software
(LCSolution,Release 1.11SP1) installed on it. Themobile phase
was degassed using Branson sonicator (Branson Ultrasonics
Corporation, USA). Absorbance spectra were recorded using
an UV–Visible spectrophotometer (Model UV-1601PC, Japan)
employing quartz cell of 1.00 cm of path length.
2.2. Softwares
Experimental design, data analysis and desirability function
calculations were performed by using Design-Expert trial
version 7.0.0. (Stat-Ease Inc., Minneapolis). The rest of the
calculations for the analysis were performed by use of Micro
soft Excel 2007 software (Microsoft, USA).
2.3. Chemicals and reagents
Working standards of rosuvastatin, ezetimibe, telmisartan,
atorvastatin and amlodipine (IS) were donated by M/S. Phar-
ma analytical Lab., Puducherry, India. Acetonitrile (MeCN)
and methanol (MeOH) were of HPLC grade and dipotassium
hydrogen phosphate and phosphoric acid were of analytical-
reagent grade supplied by M/S SD Fine Chemicals, Mumbai,
India. The HPLC grade water was prepared by using Milli-Q
Academic, Millipore, Bangalore, India. The pharmaceuticals
Rosavel EZ, (RS-10 mg with EZ-10 mg), Avas-EZ (AT-
10 mg with EZ-10 mg) and Lipisar 20 tablet (TL-20 mg with
AT-10 mg) were purchased from Sun pharmaceuticals (J&K,
Table 1 Central composite rotatable design arrangement and responsesa.
Design points Factor levels Responses
A (%v/v) B (mM) C (mL min1) k1 Rs2,3 k5
1 33 10 1 1.319 11.194 12.084
2 33 10 1 1.381 9.921 11.735
3 38 10 1 0.427 8.549 5.086
4 38 10 1 0.856 7.413 5.835
5 33 20 1 1.684 11.15 11.956
6 33 20 1 1.587 10.013 11.577
7 38 20 1 0.856 8.6 5.695
8 38 20 1 0.895 7.571 5.677
9 33 10 2 0.978 10.178 10.126
10 33 10 2 1.086 9.23 10.161
11 38 10 2 0.434 7.094 4.619
12 38 10 2 0.492 6.432 4.483
13 33 20 2 1.684 10.182 11.913
14 33 20 2 1.331 9.342 11.611
15 38 20 2 0.865 7.231 4.913
16 38 20 2 0.693 6.616 4.981
17 31.3 15 1.5 1.896 11.292 14.84
18 31.3 15 1.5 1.886 11.039 15.4
19 39.7 15 1.5 0.76 6.755 4.487
20 39.7 15 1.5 0.745 6.793 4.626
21 35.5 6.59 1.5 0.849 8.57 7.363
22 35.5 6.59 1.5 0.92 8.655 8.195
23 35.5 23.41 1.5 1.08 8.934 7.805
24 35.5 23.41 1.5 0.805 8.578 6.717
25 35.5 15 0.66 1.187 9.61 7.845
26 35.5 15 0.66 1.139 9.334 7.899
27 35.5 15 2.34 1.166 8.021 7.762
28 35.5 15 2.34 0.928 7.922 6.974
29 35.5 15 1.5 1.191 9.133 7.74
30 35.5 15 1.5 0.938 8.895 7.085
31 35.5 15 1.5 0.929 8.921 7.814
32 35.5 15 1.5 1.193 9.128 6.965
33 35.5 15 1.5 1.191 9.133 7.74
34 35.5 15 1.5 0.938 8.895 7.085
35 35.5 15 1.5 0.929 8.921 7.814
36 35.5 15 1.5 1.193 9.128 6.965
37 35.5 15 1.5 1.191 9.133 7.74
38 35.5 15 1.5 0.938 8.895 7.085
39 35.5 15 1.5 0.929 8.921 7.814
40 35.5 15 1.5 1.193 9.128 6.965
a Randomized.
Table 2 Response modelsa and statistical parameters obtained from ANOVA for CCD.
Responses regression model Model P-val. %CV Ad. prec. Adjusted R2
K1 =+ 1.06–0.34 \ A+ 0.10 \ B  0.067 \ C+ 0.075 \ A2  0.070 \ B2 <0.0001 13.45 23.317 0.8576
Rs(2,3) =+8.86–1.34 \ A  0.48 \ C <0.0001 4.14 44.697 0.9125
K5 = + 7.46  3.13 \ A+ 0.090 \ B  0.31 \ C+ 0.24 \ B \ C+ 0.83 \ A2 <0.0001 5.34 63.504 0.9759
a Only signiﬁcant coefﬁcients with P< 0.05 are included. Factors are in coded levels.
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pharmaceuticals Ltd. (Ahamedabad, India) respectively.
2.4. Standard solutions
Stock standard solutions of RS, TL, EZ and AT (1 mg/ml)
were prepared in mobile phase. The prepared stock solutionwas stored at 4 C protected from light. Working standard
solutions were freshly obtained by diluting the stock standard
solutions with mobile phase during the analysis day. Calibra-
tion curves reporting peak area ratios of RS, TL, EZ, and
AT to that of the IS versus drug concentrations were estab-
lished in the range of 0.5–5 lg/ml for RS, EZ, AT and 1–
10 lg/ml for TL in the presence of amlodipine (2.5 lg/ml) as
Figure 2 Perturbation plots showing the effect of each of the independent variables on k1, Rs2,3 and k5. Where A is the concentration of
acetonitrile, B the buffer molarity and C the mobile phase ﬂow rate.
S1382 V. Sree Janardhanan et al.internal standard. The standard solution prepared for the
optimization procedure constituted RS, TL, EZ, AT and IS
at 10.0, 10.0, 10.0, 10.0 and 5 lg/ml, respectively.
2.5. Sample preparation
Twenty tablets were weighed and ﬁnely powdered. An amount of
pharmaceutical products powder equivalent to 10 mg of RS with
10 mg of EZ, 10 mg of AT with 10 mg of EZ, and 10 mg of AT
with 20 mg of TL were accurately weighed and transferred into
a 50 ml volumetric ﬂask; suitable quantity of IS was added fol-
lowed by 25 ml of mobile phase. This mixture was subjected to
sonication for 10 min for complete extraction of drugs and the
solution was made up to the mark with a mobile phase to obtain
a concentration of RS, TL, EZ, AT and IS as 2.5, 5.0, 2.5, 2.5 and
2.5 lg/ml, respectively. The solution was centrifuged at 4000 rpm
for 10 min; the clear supernatant was collected and ﬁltered
through a 0.2 lm membrane ﬁlter (Gelman Science, India) and
20 ll of this solution was injected for HPLC analysis.
2.6. Chromatographic procedure
Chromatographic separations were carried out on a Phenome-
nexC18 analytical column (150 mm · 4.6 mm i.d., 5 lm) con-nectedwith a PhenomenexC18 guard cadridge (4 mm · 3 mm
i.d., 5 lm). Themobile phase consisted ofMeOH–MeCN–dipo-
tassiumhydrogen phosphate buffer (pH3.0), adjustedwith 10%
phosphoric acid. Wavelength of 239 nm was selected for detec-
tion. An injection volume of the sample was 20 ll. The HPLC
system was used in an air conditioned laboratory atmosphere
(20 ± 2 C).
2.7. Validation
Validation studies were conducted using the optimized assay
conditions based on the principles of validation described in
the ICH guidelines ‘‘Text on Validation of Analytical Proce-
dures’’(International Conference on Harmonization, Q2A,
1995) and ‘‘Q2B, Validation of Analytical Procedures: Meth-
odology’’ (International Conference on Harmonization, Q2B,
1997). Key analytical parameters, including, speciﬁcity, accu-
racy, precision, linearity, detection limit and quantitation limit
were evaluated. For speciﬁcity study, placebo containing
starch, lactose monohydrate, aerosil, hydroxypropyl methyl-
cellulose, titanium dioxide and magnesium stearate was used.
The calibration curve was tested using one-way ANOVA at
5% signiﬁcance level (Thanikachalam Sivakumar et al.,
2007). Calibration curves were constructed in a low region of
Figure 3 In ﬁgure (a) and (c), response surfaces related to percentage acetonitrile concentration (A) and Buffer molarity(B): Flow rate
was kept constant and in ﬁgure (b), response surfaces related to percentage acetonitrile concentration (A) and Flow rate (C): Buffer
molarity was kept constant (a) capacity factor of the ﬁrst peak (k1), (b) resolution of the critical pair (Rs2,3), (c) capacity factor of the last
peak (k5).
Table 3 Criteria for the optimization of individual responses.
Response Lower limit Upper limit Weight Criteria I Criteria II
Goal RI Goal RI
k1 0.427 1.896 1 Target = 1.2 3 Target = 1.4 5
Rs2,3 6.436 11.292 1 Range 2 Target = 8 3
k5 4.483 15.4 1 Target = 10 1 Target = 10.9 3
RI-relative importance.
Chemometric technique for the optimization of chromatographic system S13830.05–1.0% of the target analyte concentration for the limit of
detection and quantiﬁcation (Crowther, 2001). Also, robust-
ness of the proposed method was assessed with respect to small
alterations in the MeCN concentration (34.27 ± 0.5%), the
pH value (3.0 ± 0.2) and the buffer concentration
(20 ± 2.0 mM).3. Results and discussion
3.1. Data analysis and optimization design
The experimental design approach to HPLC method develop-
ment relies on two stages of experimentation: screening and
Figure 4 Bar graph showing individual desirability values of various objective responses and their association as a geometric mean (D)
corresponding to formulation samples.
Table 4 Comparison of experimental and predictive values of different objective functions under optimal conditions.
Optimum conditions MeCN (%v/v) Buﬀer (mM) Flow (mL min1) k1 Rs2,3 k5
I 34.27 20.00 2.00
Experimental 1.34 3.18 9.82
Predictive 1.22 9.04 9.22
II 33.26 19.34 2.00
Experimental 1.46 8.68 10.54
Predictive 1.40 9.57 10.90
Average error 7.0 7.9 4.9
S1384 V. Sree Janardhanan et al.optimization. The purpose of the screening is to identify the
factors that had signiﬁcant effect on the responses and to
investigate the curvature term using Factorial design with cen-
ter points. Factorial design consisting of eight factorial runs
along with six other experiments at the center of the design
points was carried out to estimate the experimental error.
The design experiments were produced in the random order.
Before starting an optimization procedure, ANOVA was gen-
erated for 2k factorial design which shows that curvature is sig-
niﬁcant for the variable (k5) since p-value is less than 0.05. This
implies that a quadratic model should be considered to model
the separation process (Ting et al., 2009). In order to obtain
second order predictive model, central composite design
(CCD) is employed, which is a design type under RSM.
CCD is chosen due to its ﬂexibility and can be applied to opti-
mize an HPLC separation by gaining better understanding of
factor’s main and interaction effects. (Wang et al., 2006a,b)
The selection of key factors examined for optimization was
based on preliminary experiments and prior knowledge from
the literature The factors selected for optimization process
were MeCN concentration (A), buffer molarity (B) and ﬂowrate (C). The capacity factor for the ﬁrst eluted peak (k1),
the resolution of the critical separated peak, RS and TL
(Rs2,3) and the capacity factor of the last peak, AT (k5), were
selected as responses. All experiments were conducted in a
randomized order to minimize the effects of uncontrolled
variables that may introduce a bias on the measurements.
Replicates (n= 6) of the central points were performed to
estimate the experimental error. Table 1, summarizes the
conducted experiments and responses. The quadratic mathe-
matical model for three independent factors is given in Eq. (1):
Y ¼ b0 þ b1X1 þ b2X2 þ b3X3 þ b12X1X2 þ b13X1X3
þ b23X2X3 þ b11X21 þ b22X22 þ b33X23 ð1Þ
where Y is the response to be modeled, b is the regression coef-
ﬁcient and X1, X2 and X3 represent factors A, B and C, respec-
tively. Statistical parameters obtained from ANOVA for the
reduced models are given in Table 2.The insigniﬁcant terms
(P> 0.05) were eliminated from the model through backward
elimination process to obtain a simple and realistic model.
Since R2 always decreases when a regressor variable is elimi-
Figure 5 Chromatograms corresponding to (A) a placebo
solution; (B) a synthetic mixture of IS (4.8 lg/ml), RS (10.2 lg/
ml), TL (10.01 lg/ml), EZ (9.98 lg/ml) and AT (9.97 lg/ml); (C) a
real sample of Rosavel-EZ containing IS (2.6 lg/ml), RS (2.5 lg/
ml) and EZ (2.52 lg/ml); (D) a real sample of Lipisar 20 tablets
containing IS (2.49 lg/ml), TL (4.97 lg/ml) and AT (2.50 lg/ml);
(E) a real sample of Avas-EZ containing, IS (2.50 lg/ml), EZ
(2.48 lg/ml) and AT (2.5 lg/ml) under optimum assay conditions
I for formulation and (F) a synthetic mixture of IS (4.9 lg/ml), RS
(9.94 lg/ml), TL (9.91 lg/ml), EZ (10.1 lg/ml) and AT (9.92 lg/
ml) under optimum assay conditions II for plasma.
Chemometric technique for the optimization of chromatographic system S1385nated from a regression model, in statistical modeling the ad-
justedR2 which takes the number of regressor variables into ac-
count, is usually selected (Parajo et al., 1992). In the present
study, the adjusted R2 were well within the acceptable limits
of R2P 0.80 (Lundstedt et al., 1998) which revealed that the
experimental data show a good ﬁt with the second-order
polynomial equations. For all the reduced models, P value of
<0.05 is obtained, implying these models are signiﬁcant. The
adequate precision value is a measure of the signal (response)
to noise (deviation) ratio. A ratio greater than 4 is desirable
(Beg et al., 2003). In this study, the ratio was found to be in
the range of 23.31–63.50, which indicates an adequate signal
and therefore the model is signiﬁcant for the separation pro-
cess. The coefﬁcient of variation (C.V.) is a measure of repro-
ducibility of the model and as a general rule a model can beconsidered reasonably reproducible if it is less than 10% (Beg
et al., 2003). The C.V. for all the models was found to be less
than 10%, except for k1 (13.45%). Hence, the diagnostic plots,
(a) normal probability plot of residuals (Choisnard et al., 2003)
and (b) plot of residuals versus predicted values (Lui and Peng,
2004) were analyzed for response k1. Since, the assumptions of
normality and constant variance of the residuals were found to
be satisﬁed; the ﬁtted model for k1 was accepted.
The interaction term with the largest absolute coefﬁcients
among the ﬁtted models is BC (+0.24) of k5 model can be seen
in Table 2. The positive interaction between B and C is statis-
tically signiﬁcant (<0.0001) for k5. The study reveals that
changing the fraction of MeCN from low to high results in a
rapid decline in the k5 of AT both at the low and high levels
of buffer molarity. Further at low level of factor A, an increase
in the buffer molarity results in a marginal decrease in k5. This
may be due to reduced silanol effects as a result of higher buf-
fer molarity used. Therefore, when the MeCN concentration is
set at its lowest level, the buffer concentration has to be at its
highest level to shorten k5. Especially this interaction is syner-
gistic, as it led to a decrease in k5.
In Fig. 2 perturbation plots are presented for predicted
models in order to gain a better understanding of the investi-
gated procedure. This type of plots shows the effect of an inde-
pendent factor on a speciﬁc response, with all other factors
held constant at a reference point (Sivakumar et al., 2007b).
A steepest slope or curvature indicates sensitiveness of the re-
sponse to a speciﬁc factor. Fig. 2 (c) shows that MeCN (factor
A) had the most important effect on capacity factor k5 fol-
lowed by factor C and then B. In Fig. 2a k1 values increased
as the levels of buffer concentration (factors B) increased while
in Fig. 2a and b k1 and Rs2,3 values decreased as the levels of
ﬂow rate (factors C) increased.
Response surfaces plots for k1, Rs2,3 and k5 are illustrated
in Fig. 3 (% acetonitrile concentration is plotted against the
ﬂow rate with buffer concentration held at constant at the cen-
ter value for Rs2,3 plot, for k1 and k5, % acetonitrile concentra-
tion is plotted against the buffer concentration with ﬂow rate
held at constant). Analysis of the perturbation plots and re-
sponse plots of optimization models revealed that factors A
and C had the signiﬁcant effect on separation of the analytes,
whereas factor B, i.e. the buffer molarity, is of little
signiﬁcance.
3.2. Derringer’s desirability function
In the present study, the identiﬁed criteria for the optimization
were: resolution between the critical peaks, capacity factors k1
and k5. Derringer’s desirability function was used to optimize
three responses with different targets (Derringer and Suich,
1980). The Derringer’s desirability function, D, is deﬁned as
the geometric mean, weighted, or otherwise, of the individual
desirability functions. The expression that deﬁnes the Derrin-
ger’s desirability function is:
D ¼ dp11  dp
2
2  dp
3
3      dp
n
n
h i1
n ð2Þ
where pi is the weight of the response, n the number of re-
sponses and di is the individual desirability function of each re-
sponse. Desirability function (D) can take values from 0 to 1.
Weights can range from 0.1 to 10. Weights lower than 1 give
less importance to the goal, whereas weights greater than 1
S1386 V. Sree Janardhanan et al.give more importance to the goal. In the present study, pi val-
ues were set at 1 for all the three responses. A value of D close
to 1, indicates that the combination of the different criteria is
matched in a global optimum (Sivakumar et al., 2007b). The
criteria for the optimization of each individual response are
shown in Table 3. Criteria I have been proposed for selecting
an optimum experimental condition for analyzing routine
quality control samples. As can be seen under criteria I, the re-
sponse k5 was targeted at 10, in order to shorten the analysis
time. On the other hand, Rs2,3 was kept in a range to allow
baseline separation of RS and TL. In order to separate the ﬁrst
eluting peak (IS) from the solvent front, k1 was targeted at 1.2.
Importance can range from 1 to 3, which gives emphasis to a
target value. Following the conditions and restrictions above,
the optimization procedure was carried out. The response sur-
face obtained for the global desirability function is presented in
Fig. 4. From the ﬁgure it can be concluded that a set of coor-
dinates producing high desirability value (D= 0.945) were
MeCN concentration of 33.27%, buffer molarity of 20 mM
and ﬂow rate of 2.00 ml/min. The predicted response values
corresponding to the above optimum condition are given in
Table 4.
To substantiate the ﬂexibility of the optimization strategy
and to search for an optimum experimental condition for ana-
lyzing plasma samples, criteria II was established by varying
the response goals and their importance values (Table 3).
For instance, high value of k1 has to be selected for the sepa-
ration of IS from the initial disturbances of plasma compo-
nents. Therefore, k1 was targeted at 1.4 and high importance
value of 5 was assigned. Following the response goals above,
the optimization procedure was carried out for which optimal
conditions II with the maximum desirability value (D= 0.837)
were MeCN concentration of 33.26%, buffer molarity of
19.34 mM and ﬂow rate of 2.00 ml/min. In order to investigate
the predictability of the proposed model, the agreement be-
tween experimental and predicted responses for both the pre-
dicted optimums I and II are shown in Table 4. The
Percentage of prediction error was calculated by Eq. (3). The
prediction efﬁciency of the model conﬁrmed by performing
the experiment under the optimal conditions I and II is also
presented Fig. 5B and F, respectively. This approach offers
ﬂexibility to the chromatographer to slide the k1 values
depending upon the environment of the analyte under
consideration.
Predicted Error ¼ Experimental Predicted=Predicted 100
ð3Þ3.3. Assay method validation
The present study was to check method’s validation for speci-
ﬁcity, linearity, accuracy, intra/inter-day precision, and robust-
ness. The method speciﬁcity was assessed by comparing the
chromatograms of standard drugs with those of placebo solu-
tions obtained from the most commonly used excipients in
pharmaceutical formulation, which included lactose monohy-
drate, aerosil, starch, hydroxy methylcellulose, magnesium
stearate and titanium dioxide, There were no excipient peaks
co- eluted with analyte and IS, indicating that the optimized
assay method is selective and speciﬁc in relation to the excipi-
ents used in this study. All placebo chromatograms showed nointerference peaks (Fig. 5). An excellent linearity was estab-
lished at ﬁve levels in the range of 0.5–1.0 lg/ml for IS, RS,
EZ and AT and 1.0–10 lg/mL for TL with R2 of more than
0.997 for all the analytes. The slope and intercept of the cali-
bration curve were 0.375 and 0.0003 for RS, 0.614 and 0.043
for TL, 0.382 and 0.002 for EZ and 0.335 and 0.0023 for
AT, respectively. Since the correlation coefﬁcients are not
good indicators of linearity performance of an analytical
procedure (Danzer and Currie, 1998) a one way ANOVA
was performed. For all the analytes, the calculated F-value
(Fcalc) was found to be less than the theoretical F-value (Fcrit)
at 5% signiﬁcance level, indicating that there was no signiﬁ-
cance difference between replicate determinations for each
concentration level. The LOD and LOQ were estimated as
0.88 and 2.66 ng/ml for RS, 0.50 and 1.51 ng/mL for TL,
1.00 and 3.02 ng/ml for EZ, and 0.75 and 2.27 ng/mL for
AT, respectively. Accuracy (n= 9), assessed by spike recovery,
were found to be 99.72%, 99.85%, 99.78% and 99.66% for
RS, TL, EZ and AT, respectively, which were within accept-
able ranges of 100 ± 2% (Kleinschmidt, 2005). The intra
and inter-assay precision (n= 6) was conﬁrmed since, the %
C.V. were well within the target criterion of 62 and 63, respec-
tively (Kleinschmidt, 2005). Robustness study reveals that
small changes did not alter the retention times, retention factor
and resolutions more than 4% and therefore it would be con-
cluded that the method conditions are robust.
3.4. Application of the method
The proposed RP-HPLC method was applied to the quantita-
tive analysis of real samples, three commercial tablet products
Rosavel EZ tablet (RS-10 mg with EZ-10 mg), Avas-EZ tablet
(AT-10 mg with EZ-10 mg) and Lipisar 20 tablet (TL-20 mg
with AT-10 mg) were assayed by the proposed HPLC method.
Representative chromatograms are presented in Fig. 5. The re-
sults achieved when analyzing Rosavel EZ tablets were, 9.98
(0.97) mg of RS and 10.01 (1.11) mg of EZ; Avas- EZ tablets
were, 10.02 (1.38) mg of AT and 10.02 (1.05) mg of EZ and
Lipisar 20 tablet were, 20.06 (0.44) mg of TL and 10.08
(1.38) mg of AT with the values within parenthesis being the
% C.V. of the six replicates. Good agreement was found be-
tween the assay results and the label claim of the product.
The % C.V. for tablets were <2, indicating the precision of
the analytical methodology. The mean recoveries for each ana-
lyte were also tested for signiﬁcance to establish whether the
recovery means are different from the label claim of the tablets
by employing Student’s t-test.
4. Conclusions
Statistically based experimental designs proved to be a valu-
able approach in optimizing selectivity-controlling parameters
for the simultaneous estimation of the analytes RS, TL, EZ,
and AT in pharmaceutical formulations (tablets). The devel-
oped HPLC method could be of immense relevance and value
since cardiovascular therapy usually involves different combi-
nation of antihypertensive and lipid lowering drugs. Therefore
the simultaneous determination of these analytes becomes sig-
niﬁcant. This method reduces overall assay development time
and provides essential information regarding the sensitivity
of various chromatographic factors and their interaction ef-
Chemometric technique for the optimization of chromatographic system S1387fects on the attributes of separation. Time of analysis, resolu-
tion and quality of the peaks were simultaneously optimized
by applying useful tools of chemometrics: central composite
design and Derringer’s desirability function. The validation
study supported the selection of the assay conditions by con-
ﬁrming that the assay was speciﬁc, accurate, linear, precise,
and robust. Therefore, this HPLC method can be used as a
routine quality control analysis in a pharmaceutical environ-
ment. The results of the study demonstrate the beneﬁt of
applying this approach in selecting optimum conditions for
the determination of drugs in pharmaceutical formulation
and plasma samples.
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